UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010333
Receipt number R000012095
Scientific Title Study of step-down therapy from formoterol/budesonide combinations in patients with asthma
Date of disclosure of the study information 2013/03/27
Last modified on 2013/09/27 20:18:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of step-down therapy from formoterol/budesonide combinations in patients with asthma

Acronym

Step-down therapy from formoterol/budesonide combinations

Scientific Title

Study of step-down therapy from formoterol/budesonide combinations in patients with asthma

Scientific Title:Acronym

Step-down therapy from formoterol/budesonide combinations

Region

Japan


Condition

Condition

Asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To estimate the efficacy and safety of the step-down therapy in patients with bronchial asthma

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Asthma attack during the treatment period

Key secondary outcomes

Lung function during the treatment period
QOL score during the treatment period
FeNO during the treatment period
Adverse events during the treatment period


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Switch from budesonide/formoterol (Symbicort)160/4.5ug two inhalation twice daily to one inhalation twice daily for 12 weeks

Interventions/Control_2

Switch from budesonide/formoterol (Symbicort)160/4.5ug two inhalation twice daily to budesonide (Pulmicort) 200ug two inhalation twice daily for 12 weeks

Interventions/Control_3

Switch from budesonide/formoterol (Symbicort)160/4.5ug two inhalation twice daily to mometasone(asmanex) 200ug one inhalation twice daily for 12 weeks

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Ability and willingness to provide informed consent
Budesonide/formoterol (Symbicort) 160/4.5ug two inhalation twice daily at constant dose for 2 months
Achieve good control of the GINA criteria

Key exclusion criteria

History of presence of lung, cardiac, renal and liver disease

Target sample size

150


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takafumi Suda

Organization

Hamamatsu University School of Medicine

Division name

Second Division, Department of Internal Medicine

Zip code


Address

1-20-1,Handayama,Higashi-ku,Hamamatsu-shi,Shizuoka,431-3192 Japan

TEL

053-435-2263

Email

suda@hama-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Dai Hashimoto

Organization

Hamamatsu University School of Medicine

Division name

Second Division, Department of Internal Medicine

Zip code


Address

1-20-1,Handayama,Higashi-ku,Hamamatsu-shi,Shizuoka,431-3192 Japan

TEL

053-435-2263

Homepage URL


Email

dai@hama-med.ac.jp


Sponsor or person

Institute

Hamamatsu University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

浜松医科大学医学部附属病院(静岡県)


Other administrative information

Date of disclosure of the study information

2013 Year 03 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2013 Year 03 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 03 Month 27 Day

Last modified on

2013 Year 09 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012095


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name